NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal (Committee C) meeting minutes

## Committee members Present:

* Chair Professor Stephen O’Brien Present for all notes
* Vice Chair Dr Peter Selby Present for all notes
* Dr Alex Cale Present for all notes
* Michael Chambers Present for all notes
* Dr David Foreman Present for all notes
* John Hampson Present for all notes
* Dr Nigel Langford Present for all notes
* Kirandip Moyo Present for all notes
* Iain McGowen Present for all notes
* Dr Mudasar Mushtaq Present for all notes
* Dr Richard Nicholas Present for all notes
* Ugochinyere Nwula Present for all notes
* Stella O’Brien Present for all notes
* Professor Subhash Pokhrel Present for all notes
* Professor Matt Stevenson Present for all notes
* Dr Derek Ward Present for all notes

## NICE Staff In attendance:

* Jasdeep Hayre, Associate Director, NICE, Present for all notes
* Kate Moore, Project Manager, NICE, Present for all notes
* Thomas Paling, Technical Analyst, NICE, Present for all notes
* Nicola Hay, Technical Adviser, NICE, Present for all notes
* Celia Mayers, Administrator, NICE, Present for all notes
* John Stevens, ScHARR, Evidence Review Group, Present for notes 1 to 7
* Paul Tappenden, ScHARR, Evidence Review Group, Present for notes 1 to 7
* Lesley Uttley, ScHARR, Evidence Review Group, Present for notes 1 to 7
* Dr Marianna Fontana, Clinical expert nominated by British Cardiovascular Society, Present for notes 1 to 7
* Professor Philip Hawkins, Clinical expert nominated by University College London Hospital NHS Foundation Trust, Present for notes 1 to 7
* David Gregory, Patient expert, Present for notes 1 to 7
* Vincent Nicholas, Patient expert, Present for 1 to 7
* Paul Pozzo, Patient expert, Present for notes 1 to 7
* Dr Ayesha Ali, NHS Commissioning expert, nominated by NHS England, Present for notes 1 to 7

## Non-public attendees:

* Sarah Bromley, Editor, NICE, Present for all notes
* Jack Brownrigg, Company representative, Present for notes 1 to 7
* Henry Edwards, NICE observer, Present for all notes
* Toni Gasse, NICE observer. Present for all notes
* Olivia Havercroft, Editor, NICE, Present for all notes
* Lesley Hayes, NICE observer, Present for all notes
* Joanne Holden, NICE observer, Present for all notes
* Debra Hunter, NICE observer, Present for all notes
* Katherine Lanyi, NICE observer, Present for all notes
* Sam Large, Company representative, Present for notes 1 to 7
* Vonda Murray, NICE observer, Present for all notes
* Niamh O’Dell, NICE observer, Present for all notes
* Adam O Keefe, NICE observer, Present for all notes
* Mandy Tonkinson, Public Involvement adviser, NICE, Present for notes 1 to 7

### Notes

### Any other Business

1. None

## Appraisal of Tafamidis for treating transthyretin amyloid cardiomyopathy [ID1531]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG)/Assessment Group (AG) representatives and representatives from Pfizer.
2. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests

	1. Matt Stevenson declared non-financial professional & personal Interests as he is a director of ScHARR-TAG, the ERG for this appraisal.
		1. It was agreed that this declaration would not prevent Matt Stevenson from participating in this section of the meeting and noted that he will not be a voting member on this appraisal.
	2. Professor Andrea Manca excused himself from this meeting on grounds of confliction, as he received consultancy fee from manufacturer for participation in an Advisory Board relating to this product.
3. No further conflicts of interest were declared for this appraisal.
4. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
5. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

## Part 2 – Closed session (company representatives, clinical and patient experts and members of the public were asked to leave the meeting)

1. The committee discussed confidential information submitted as part of this appraisal.
2. Agreement on the content of the Appraisal Consultation Document (ACD) was discussed by the committee.
3. A vote was taken. The options were:
Option 1: ICER range
Option 2: Managed access arrangement

Option 3: Only in research (oir) option

11. The committee voted for Option 1

12. Date of the next meeting

The next meeting of the Technology Appraisal (Committee C) will be held on Tuesday 2 June 2020.